Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05323253 · ClinicalTrials.gov registry record · NA
A Clinical Study to Assess the Efficacy and Safety of Alpha DaRT224 for the Treatment of Patients With Recurrent Cutaneous Squamous Cell Carcinoma
A NA study of Recurrent Squamous Cell Carcinoma, sponsored by Alpha Tau Medical.
- Recruiting
- Registry status
- NA
- Development phase
- 86
- Enrollment target
- 20
- Study locations
NCT05323253 is a NA study of Recurrent Squamous Cell Carcinoma that is actively recruiting participants, run by Alpha Tau Medical. The registered enrollment target is 86 participants. The trial reports 20 study locations across 8 states.
The verdict
NCT05323253, a NA study of Recurrent Squamous Cell Carcinoma, is actively recruiting participants, sponsored by Alpha Tau Medical.
- RECRUITING
- Registry status
- NA
- Development phase
- 86 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multi-center clinical study enrolling up to 86 participants. The primary objectives are to determine the objective response rate (ORR) established by the confirmed best overall response (BOR) following intratumoral administration of DaRT - Diffusing Alpha-Emitters Radiation Therapy, as well as to assess the Duration of Response (DOR) 6 months from initial response. Secondary objectives are to assess the safety of DaRT, and to assess the progression free survival (PFS), overall survival (OS), Overall Duration of Response (O-DOR), local control and quality of life (QOL) for patients treated with DaRT.
Conditions Studied
Interventions
- DEVICE DaRT seeds
Study Locations (20)
Florida
- Day Star Skin and Cancer Center - DeLand
- Integrity Research Clinical Associates - Delray Beach
- Palm beach Dermatology Group - Delray Beach
- Hollywood Dermatology - Hollywood
- University of Miami - Miami
- Baptist Health South Florida MCI - Miami
- Moffitt Cancer Center - Tampa
- Beer Dermatology - West Palm Beach
New York
- Bassett Healthcare Network - Cooperstown
- Northwell Health - Queens
- New York Medical Skin Solutions - Rockaway Park
- MDCS Dermatology - Smithtown
Arizona
- Banner Health MD Anderson Phoenix - Gilbert
- Dignity Health Cancer Institute - Phoenix
- Alliance Dermatology - Phoenix
California
- UCLA - Los Angeles
Georgia
- Emory University - Atlanta
Minnesota
- Mayo Clinic Rochester - Rochester
New Jersey
- Schweiger Dermatology Group - Hackensack
New Mexico
- New Mexico Cancer Center - Albuquerque
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2022-09-21 |
| Est. Completion | 2025-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05323253
The ClinicalTrials.gov registry entry for NCT05323253 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alpha Tau Medical, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Recurrent Squamous Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which DaRT seeds is the first listed.
NCT05323253 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Florida, New York, Arizona.
Frequently Asked Questions
What is clinical trial NCT05323253 about?
NCT05323253 is a clinical study titled "A Clinical Study to Assess the Efficacy and Safety of Alpha DaRT224 for the Treatment of Patients With Recurrent Cutaneous Squamous Cell Carcinoma". This is a multi-center clinical study enrolling up to 86 participants. The primary objectives are to determine the objective response rate (ORR) established by the confirmed best overall response (BOR) following intratumoral administration of DaRT - Diffusing Alpha-Emitters Radiation Therapy, as wel...
What is the current status of trial NCT05323253?
This trial is currently recruiting. It is a NA study. The enrollment target is 86 participants. The study started on 2022-09-21. Estimated completion is 2025-12.
What conditions does trial NCT05323253 study?
This clinical trial studies the following conditions: Recurrent Squamous Cell Carcinoma.
What interventions are being tested in trial NCT05323253?
The interventions under investigation include: DaRT seeds (DEVICE).
Who is sponsoring clinical trial NCT05323253?
This trial is sponsored by Alpha Tau Medical, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05323253 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.